Clinical Trial Update: Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating short-course radiotherapy followed by CAPOX and immunotherapy with camrelizumab plus either bevacizumab or cetuximab for unresectable m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Rectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Camrelizumab (camrelizumab)
• Capecitabine (Xeloda) (Capecitabine)
• Cetuximab (Erbitux) (Cetuximab)
• Oxaliplatin (Eloxatin) (oxaliplatin)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Unresectable Metastatic Rectal Cancer, CAPOX | Phase 2 | Status: NOT_YET_RECRUITING